EDIT Editas Medicine Inc.

Editas Medicine to Participate in Upcoming Investor Conferences

Editas Medicine to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that management will participate in the following upcoming investor conferences:

Citi’s 15th Annual BioPharma Virtual Conference

Panel: Innovation in Cell Therapy

Date: Wednesday, September 9, 2020

Time: 3:20 p.m. ET

Wells Fargo 2020 Virtual Healthcare Conference

Fireside Chat

Date: Thursday, September 10, 2020

Time: 10:40 a.m. ET

Morgan Stanley 18th Annual Global Healthcare Conference

Fireside Chat

Date: Tuesday, September 15, 2020

Time: 10:15 a.m. ET

The events will be webcast live and may be accessed on the Editas Medicine website in the Investors and Media section. Archived recordings will be available for approximately 30 days following the events.

About Editas Medicine

As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit

Investor Contact

Mark Mullikin

(617) 401-9083

Media Contact

Cristi Barnett

(617) 401-0113

EN
04/09/2020

Underlying

EDITEditas Medicine Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Editas Medicine Inc.

 PRESS RELEASE
Free
EDIT Editas Medicine...

Editas Medicine Announces Third Quarter 2025 Results and Business Upda...

Editas Medicine Announces Third Quarter 2025 Results and Business Updates In vivo preclinical proof-of-concept data presented at AHA and ESGCT demonstrating >90% LDL-C reduction in non-human primates supports EDIT-401’s potential as a best-in-class, one-time therapy Company on track to submit IND/CTA for EDIT-401 by mid-2026 and achieve initial human proof-of-concept data by year-end 2026 Extended cash runway into the third quarter of 2027, enabling progression of EDIT-401 beyond initial human proof-of-concept data CAMBRIDGE, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Editas Medicine...

November 10, 2025 1 EN
 PRESS RELEASE
Free
EDIT Editas Medicine...

Editas Medicine Announces EDIT-401 Poster Presentation at the American...

Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025 CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced a moderated digital poster presentation at the upcoming American Heart Association (AHA) Scientific Sessions 2025 to be held November 7-10 in New Orleans, Louisiana. American Heart Association (AHA) Scientific Sessions 2025Title: A transformative LDL cholesterol–l...

November 3, 2025 1 EN
 PRESS RELEASE
Free
EDIT Editas Medicine...

Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at ...

Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress Preclinical data demonstrates proof-of-concept for EDIT-401 with ≥90% mean LDL-C reduction in non-human primates and mouse models CAMBRIDGE, Mass., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today reported in vivo preclinical proof-of-concept data for EDIT-401, an experimental, potential best-in-class, one-time therapy to significantly reduce LDL-cholesterol (LDL-C), at the 32nd An...

October 9, 2025 1 EN
 PRESS RELEASE
Free
EDIT Editas Medicine...

Editas Medicine Announces EDIT-401 Oral Presentation at the European S...

Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences CAMBRIDGE, Mass., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced an oral presentation at the upcoming European Society of Gene and Cell Therapy (ESGCT) Congress, to be held October 7-10, 2025, in Seville, Spain. European Society of Gene and Cell Therapy (ESGCT) Congr...

October 6, 2025 1 EN
 PRESS RELEASE
Free
EDIT Editas Medicine...

Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead...

Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into second quarter of 2027 Company-sponsored webinar on EDIT-401 today at 8:00 a.m. ET CAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today announced the nomination of its lead in vivo development candidate, EDIT-401,...

September 2, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch